Biologics for severe asthma
Biologic agents target specific aspects of a disease process and so present an opportunity for effective, selective therapy. They can be highly engineered to fine-tune their pharmacologic properties for maximum clinical benefit.1-2
The inflammatory cascade in asthma is a complex process and there may be emphasis on certain pathways depending on the disease subtype. 3-4A variety of monoclonal antibodies against inflammatory cytokines, chemokines or their receptors have reached or are approaching the market.4-5These biologics have the potential to both treat and further define specific severe asthma phenotypes, because they target a specific underlying mechanism of disease.